Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma

Inclusion Criteria: * The patient or their guardian understands and voluntarily signs the informed consent form and is expected to complete the study's follow-up assessments and treatments. Age between 18 and 75 years, with no gender restrictions. Diagnosis of multiple myeloma according to the International Myeloma Working Group (IMWG) criteria. Documented evidence of relapsed/refractory or primary refractory multiple myeloma, defined as follows: Relapsed/Refractory: Lack of response to salvage therapy (defined as no minimal response (MR) or disease progression during treatment), or disease progression within 60 days of the last treatment, or progression after achieving MR or better. Primary Refractory: No response (MR or better) to any previous treatment, with no clinical progression or minimal M-protein change, or meeting criteria for primary refractory progression. Presence of measurable disease at screening by any of the following criteria: serum M-protein ≥ 1.0 g/dL, urine M-protein ≥ 200 mg/24 hours, or for light-chain myeloma without measurable disease in serum or urine, serum free light chain (FLC) ≥ 10 mg/dL with abnormal serum immunoglobulin κ/λ FLC ratio. Resolution of prior treatment-related toxicities to Grade \<2 per CTCAE (unless related to underlying malignancy or deemed stable and not impacting safety or efficacy). ECOG performance status 0-2 and an expected survival of more than 3 months. Laboratory values meeting the following standards, indicating…